Our data suggested that the survival benefit of PDCD4 in intracranial metastases is present regardless of where PDCD4 is expressed in the tumor cells (either nuclear or in the nucleus/cytoplasm) or stroma. This evidence concerns the gene PDCD4 and neoplasm.